Latest Earnings Released (Q3 FY25): Reported quarterly statutory revenue of ₹133.79 Cr with net profit of ₹0.72 Cr (EPS: ₹0.26).
Exchange Disclosure (2026-10-08): Certificate under SEBI (Depositories and Participants) Regulations, 2018 — Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 — Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Official listing profile for Aarey Drugs & Pharmaceuticals Limited under Diversified.
Official listing profile for Aarey Drugs & Pharmaceuticals Limited under Diversified.
Commercial & Industrial
- Strong YoY revenue expansion (378.3%)
- High net earnings expansion (248.0%)
- Superior Return on Equity (77.0%)
- Conservative leverage profile (D/E 0.24)
- Superior capital efficiency (ROCE 71.4%)
- No severe solvency or structural stress flags detected.
| Annual Metric (₹ Cr) | FY24 Dec 2023 | FY25 Dec 2024 |
|---|---|---|
| Sales / Revenue from Operations | ₹76 | ₹366 |
| Operating Profit (EBITDA) | ₹1.17 | ₹2.20 |
| Operating Profit Margin (OPM %) | 1.53% | 0.60% |
| Finance Costs / Interest | N/A | N/A |
| Depreciation & Amortization | N/A | N/A |
| Profit Before Tax (PBT) | ₹1.47 | ₹4.48 |
| Net Profit (PAT) | ₹1.02 | ₹3.55 |
| Net Profit Margin (NPM %) | 1.33% | 0.97% |
| Basic / Diluted EPS (₹) | ₹0.40 | ₹2.28 |
| Cash from Operations (CFO) | ₹7.89 | N/A |
| Free Cash Flow (FCF) | ₹7.89 | N/A |
| Quarterly Metric (₹ Cr) | Q3 FY24 Dec 2023 | Q4 FY24 Mar 2024 | Q1 FY25 Jun 2024 | Q2 FY25 Sep 2024 | Q3 FY25 Dec 2024 |
|---|---|---|---|---|---|
| Sales / Revenue | ₹76 | ₹210 | ₹127 | ₹105 | ₹134 |
| Operating Profit (EBITDA) | ₹1.17 | ₹-2.99 | ₹-0.24 | ₹1.73 | ₹0.72 |
| OPM % | 1.53% | -1.42% | -0.19% | 1.65% | 0.54% |
| Profit Before Tax (PBT) | ₹1.47 | ₹2.15 | ₹1.33 | ₹1.75 | ₹1.40 |
| Net Profit (PAT) | ₹1.02 | ₹2.15 | ₹1.24 | ₹1.60 | ₹0.72 |
| NPM % | 1.33% | 1.02% | 0.98% | 1.52% | 0.54% |
| Basic / Diluted EPS (₹) | ₹0.40 | ₹0.77 | ₹0.88 | ₹1.14 | ₹0.26 |
| Balance Sheet Item (₹ Cr) | FY24 | FY25 |
|---|---|---|
| Equity Share Capital | ₹28 | N/A |
| Reserves & Surplus | ₹105 | N/A |
| Net Worth (Shareholders' Funds) | ₹133 | N/A |
| Total Borrowings & Debt | ₹31 | N/A |
| Total Balance Sheet Assets | ₹305 | N/A |
| Cash Flow Item (₹ Cr) | FY24 | FY25 |
|---|---|---|
| Cash Flow from Operating Activities (CFO) | ₹7.89 | N/A |
| Cash Flow from Investing Activities (CFI) | ₹-7.32 | N/A |
| Cash Flow from Financing Activities (CFF) | ₹4.10 | N/A |
| Free Cash Flow / Net Cash Flow | ₹7.89 | N/A |
| Financial Ratio / Efficiency Metric | FY24 | FY25 |
|---|---|---|
| Operating Profit Margin (OPM) | 1.53% | 0.60% |
| Net Profit Margin (NPM) | 1.33% | 0.97% |
| Return on Equity (ROE) | 0.77% | N/A |
| Return on Capital Employed (ROCE) | 0.71% | N/A |
| Return on Assets (ROA) | 0.33% | N/A |
| Debt to Equity Ratio | 0.24x | N/A |
| Interest Coverage Ratio | N/A | N/A |
| CFO to Net Profit Conversion | 7.74x | N/A |
DIN: 00581005 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 07069841 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 01639366 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 01652630 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 08291619 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
DIN: 01471745 | Verified Board Member per SEBI LODR Reg 27 Corporate Governance Filing.
| Type | Ex-Date | Record Date | Amount / Ratio | Description |
|---|---|---|---|---|
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹2.00 | Final Dividend - Rs. - 2.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹7.00 | Final Dividend - Rs. - 7.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.50 | Final Dividend - Rs. - 0.5000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹5.00 | Final Dividend - Rs. - 5.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.55 | Final Dividend - Rs. - 0.5500 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹25.00 | Final Dividend - Rs. - 25.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹3.00 | Final Dividend - Rs. - 3.0000 |
| CORPORATE_ACTION | 2026-09-15 | 2026-09-15 | N/A | Right Issue of Equity Shares |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹1.00 | Final Dividend - Rs. - 1.0000 |
| DIVIDEND | 2026-09-15 | 2026-09-15 | ₹0.30 | Final Dividend - Rs. - 0.3000 |
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about General Updates
Aarey Drugs & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report and voting results of Annual General Meeting held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about General Updates
Aarey Drugs & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report and voting results of Annual General Meeting held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Final Dividend - Rs. - 2.0000
Final Dividend - Rs. - 7.0000
Final Dividend - Rs. - 0.5000
Final Dividend - Rs. - 5.0000
Every financial metric, balance-sheet balance, and shareholding breakdown displayed on this dossier is grounded in primary statutory filings submitted to Indian stock exchanges (SEBI LODR Regulations 31, 33, and 47). No data is manufactured, estimated, or interpolated.
| Data Domain | Reporting Period | Statutory Source | Ingestion Date | Status | Provenance Hash |
|---|---|---|---|---|---|
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 03 Nov 2026, 09:50 | VERIFIED | 98d30cd3dfd9... |
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 31 Oct 2026, 05:46 | VERIFIED | f870aff170f7... |
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 28 Oct 2026, 05:32 | VERIFIED | 640d0890e7f0... |
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 25 Oct 2026, 13:33 | VERIFIED | e3a6d951ce70... |
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 21 Oct 2026, 15:45 | VERIFIED | 21fc4cd63f0c... |
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 17 Oct 2026, 05:45 | VERIFIED | 7cbc8fd95590... |
| financials_quarterly | SCHEDULED_CHECK | NSE_OFFICIAL_API | 12 Oct 2026, 14:45 | VERIFIED | 4ee08adf7d16... |
DATA SOURCES, STATUTORY DISCLOSURES & METHODOLOGY
All corporate identifiers, listed equity data, shareholding patterns, and financial statements are extracted from official regulatory authorities: National Stock Exchange of India (NSE), BSE Limited, and Ministry of Corporate Affairs (MCA) via audited XBRL Ind-AS submissions under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations 31, 33, and 47). Data is ingested and archived on official end-of-day (EOD) schedules with immutable provenance tracking.
Zero-Fabrication Policy: SRK Money Talk strictly enforces authentic data integrity. No financial values, debt levels, cash flows, or quarterly earnings are ever mathematically synthesized, interpolated, or fabricated. When statutory disclosures have not yet been filed or ingested, fields are strictly labeled as N/A or NOT_YET_AVAILABLE.
Statutory Disclaimer: The SRK Fundamental Health Score is a quantitative diagnostic algorithm based exclusively on historical audited filings and does not constitute an investment recommendation or financial advisory. Always consult a SEBI-registered investment adviser before making capital allocation decisions.